MeDUsA: A novel system for automated axon quantification to evaluate neuroaxonal degeneration
MeDUsA: A novel system for automated axon quantification to evaluate neuroaxonal degeneration
复制标题
DOI:
10.1101/2021.10.25.465674
复制
发表时间:
2021-10
期刊:
影响因子:
--
通讯作者:
Yohei Nitta;H. Kawai;Jiro Osaka;Satoko Hakeda-Suzuki;Y. Nagai;K. Doubková;Takashi Suzuki;G. Tavosanis;Atsushi Sugie
中科院分区:
文献类型:
--
作者:
Yohei Nitta;H. Kawai;Jiro Osaka;Satoko Hakeda-Suzuki;Y. Nagai;K. Doubková;Takashi Suzuki;G. Tavosanis;Atsushi Sugie
Background Drosophila is an excellent model organism for studying human neurodegenerative diseases (NDs), and the rough eye phenotype (REP) assay is a convenient experimental system for analysing the toxicity of ectopically expressed human disease genes. However, the association between REP and axonal degeneration, an early sign of ND, remains unclear. To address this question, we developed a method to evaluate axonal degeneration by quantifying the number of retinal R7 axons in Drosophila; however, it requires expertise and is time-consuming. Therefore, there is a need for an easy-to-use software that can automatically quantify the axonal degeneration. Result We created MeDUsA (a ‘method for the quantification of degeneration using fly axons’), which is a standalone executable computer program based on Python that combines a pre-trained deep-learning masking tool with an axon terminal counting tool. This software automatically quantifies the number of axons from a confocal z-stack image series. Using this software, we have demonstrated for the first time directly that axons degenerate when the causative factors of NDs (αSyn, Tau, TDP-43, HTT) were expressed in the Drosophila eye. Furthermore, we compared axonal toxicity of the representative causative genes of NDs and their pathological alleles with REP and found no significant correlation between them. Conclusions MeDUsA rapidly and accurately quantifies axons in Drosophila eye. By simplifying and automating time-consuming manual efforts requiring significant expertise, it enables large-scale, complex research efforts on axonal degeneration, such as screening to identify genes or drugs that mediate axonal toxicity caused by ND disease proteins.